| Literature DB >> 31512848 |
Neetu Dayal1, Clement Opoku-Temeng1,2, Haroon Mohammad3, Nader S Abutaleb3, Delmis Hernandez1, Kenneth Ikenna Onyedibe1,4, Modi Wang1, Matthias Zeller1, Mohamed N Seleem3,4, Herman O Sintim1,4.
Abstract
Staphylococcus aureus can survive both inside and outside of phagocytic and nonphagocytic host cells. Once in the intracellular milieu, most antibiotics have reduced ability to kill S. aureus, thus resulting in relapse of infection. Consequently, there is a need for antibacterial agents that can accumulate to lethal concentrations within host cells to clear intracellular infections. We have identified tetrahydrobenzo[a or c]phenanthridine and tetrahydrobenzo[a or c]acridine compounds, synthesized via a one-flask Povarov-Doebner operation from readily available amines, aldehydes, and cyclic ketones, as potent agents against drug-resistant S. aureus. Importantly, the tetrahydrobenzo[a or c]phenanthridine and tetrahydrobenzo[a or c]acridine compounds can accumulate in macrophage cells and reduce the burden of intracellular MRSA better than the drug of choice, vancomycin. We observed that MRSA could not develop resistance (by passage 30) against tetrahydrobenzo[a or c]acridine compound 15. Moreover, tetrahydrobenzo[c]acridine compound 15 and tetrahydrobenzo[c]phenanthridine compound 16 were nontoxic to red blood cells and were nonmutagenic. Preliminary data indicated that compound 16 reduced bacterial load (MRSA USA300) in mice (thigh infection model) to the same degree as vancomycin. These observations suggest that compounds 15 and 16 and analogues thereof could become therapeutic agents for the treatment of chronic MRSA infections.Entities:
Keywords: antibiotic resistance; antistaphylococcal agents; intracellular infection clearance; macrophage cells; tetrahydrobenzo[a or c]acridine; tetrahydrobenzo[a or c]phenanthridines
Mesh:
Substances:
Year: 2019 PMID: 31512848 DOI: 10.1021/acsinfecdis.9b00022
Source DB: PubMed Journal: ACS Infect Dis ISSN: 2373-8227 Impact factor: 5.084